# Jazz Pharmaceuticals

Type: Company

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/jazz-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/jazz-pharmaceuticals

## Timeline

- **2026-Q4**: Anticipated Regulatory Milestones — Potential for further regulatory filings based on ongoing Phase 3 data.
- **2026-04-20**: AACR Annual Meeting — Expected dates for the 2026 AACR meeting where Ziihera data will be showcased.
- **2026-03-18**: Presentation Announcement — Zymeworks announces multiple abstracts accepted for AACR 2026.

## Recent coverage (2 stories)

### Zymeworks to Present Key Ziihera Clinical Data at 2026 AACR Annual Meeting
2026-03-18 13:15:18 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Zymeworks Inc. (ZYME) has announced multiple upcoming presentations for its lead asset, Ziihera (zanidatamab-hrii), at the 2026 AACR Annual Meeting. These presentations are expected to showcase the therapeutic's efficacy and safety across various HER2-expressing cancers, reinforcing its position in the competitive oncology landscape.
Full story: https://getbiobrief.com/story/zymeworks-ziihera-aacr-2026-presentations

### Cannabis Compounds Show Potential to Reverse MASLD in One-Third of Adults
2026-03-10 03:37:36 · Sentiment: Positive · Impact: 6/10 · Sources: 2

Emerging research indicates that specific non-psychoactive cannabis compounds, particularly THCV, may reverse Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). This breakthrough offers a potential pharmaceutical path for a condition that currently affects nearly 33% of the global adult population.
Full story: https://getbiobrief.com/story/cannabis-compounds-reverse-liver-disease-masld

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.